Aldehyde dehydrogenase 1A1 in stem cells and cancer

Tomita, Hiroyuki; Tanaka, Kaori; Tanaka, Takuji; Hara, Akira

doi:10.18632/oncotarget.6920

Cited by 513 publications

(544 citation statements)

References 93 publications

Supporting

Mentioning

482

Contrasting

Unclassified

Order By: Relevance

“…The ALDH1 isoforms (including ALDH1A1) play a role in retinoic acid formation through the oxidation of all-trans-retinal and 9-cis-retinal, which are involved in retinoid signaling, which is related to the stemness of CSCs and normal tissue SCs (10-13). ALDH1A1 activity also has a known role in drug resistance (10,14) and radioresistance (15).…”

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma

Miyata

Oyama

Yoshimatsu

et al. 2017

View full text Add to dashboard Cite

Abstract. Background/Aim: Aldehyde dehydrogenase-1A1 (ALDH1A1) and CD133 have been identified as markers of cancer stem cells (CSCsDespite continuous efforts to improve therapeutic response, lung cancer is the most common cause of cancer-related deaths in Japan, with adenocarcinoma by far the most common histology, accounting for nearly 70% of lung cancer cases (1). Cancer stem cells (CSCs) have the ability for selfrenewal and multipotently differentiate (2). CSCs may be highly resistant to chemotherapy and radiation, and be responsible for tumor initiation, progression and metastasis (3, 4). Accumulating evidence supports the existence of a CSC phenotype in human lung cancer (3, 5-7). The metabolic marker aldehyde dehydrogenase isoform 1A1 (ALDH1A1) and the cell-surface marker CD133 are reported to be markers of lung CSCs (3). We, therefore, investigated ALDH1A1 and CD133 expression in a retrospective cohort of 92 patients with lung adenocarcinoma. The objectives were to determine the association between ALDH1A1 and CD133 expression in lung adenocarcinoma, the relationship between their expression and the clinichopathological parameters, and the prognostic value of ALDH1A1 and CD133. Materials and MethodsPatient population and clinicopathological data. We examined a series of 154 Japanese patients with lung adenocarcinoma who underwent surgical treatment at Fukuoka-Wajiro Hospital, Fukuoka, Japan from 2006-2012. Ninety-two out of 154 (59.7%) patients were selected based on the following inclusion criteria: (i) no chemotherapy or radiotherapy before surgery, and (ii) the availability of an adequate paraffin block and clinicopathological data for the analysis. Follow-up information was obtained from the patients' records. Routinely collected clinicopathological data included age, gender, smoking history and pathological stage. There were 49 males (53%) and 43 females (47%), with a median age of 71 years (range=40-92 years) at the time of surgery; 43 (47%) patients were <70 years and 49 (53%) were ≥70 years of age. Half of the patients (n=46) had a smoking history. The pathological stages were: stage I, n=62 (67.4%); stage II, n=14 (15.2%); stage III, n=12 (13.0%); and stage IV, n=4 (4.4%) (TNM staging of lung cancer) (8). The median follow-up period was 1,702 days (range=4-3679 days). Recurrence was diagnosed by computed tomography alone or combined with positron-emission tomography.

show abstract

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma

Miyata

Oyama

Yoshimatsu

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In retinoid signaling, retinol dehydrogenases oxidize the retinol absorbed by cells to retinal [93]. Retinal is then oxidized to RA in a reaction catalyzed by ALDH1 family members such as ALDH1A1, ALDH1A2, and ALDH1A3.…”

Section: Aldh1 In Retinoid Signalingmentioning

confidence: 99%

“…Interestingly, ALDH bright cells are atributed to ALDH1 activity. Thus, ALDH1 expression in immunohistochemistry is considered to be slightly diferent from ALDH bright cells in HCC [93].…”

Section: Aldh1 In Hccmentioning

confidence: 99%

Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers

Tomita¹,

Kanayama²,

Niwa³

et al. 2017

Updates in Liver Cancer

Self Cite

View full text Add to dashboard Cite

The cancer stem cell (CSC) theory posits that a small population of cells with stem celllike features is responsible for tumor growth, resistance, and recurrence in many malignancies. This theory could be a useful paradigm for designing innovative targeted drug therapies. Liver cancer is the ifth most common cancer worldwide, with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) as the predominant forms. Hepatic stem/progenitor cells are believed to be the origin of HCCs and CCAs; however, this remains a controversial topic. Aldehyde dehydrogenase (ALDH) is the main enzymatic system responsible for the clearance of acetaldehyde from the hepatocytes in the liver tissue. Therefore, ALDH1 has been suggested to be a potential, biological and CSC marker in liver cancers. We here provide an overview of the current state of knowledge of CSCs in liver and the role of ALDH1 in the development and progression of liver cancers and discuss its potential value as a prognostic and diagnostic biomarker.

show abstract

“…Hence, IHC has several advantages over IF technique including: 1) capability of being repeatedly used in order to search for few positive cells, 2) no reduction in signal intensity, 3) provides superior morphological information, and 4) could be utilized to distinguish between normal and cancerous tissue. Therefore, in cancerous tissues, double-staining IHC is practically suitable for observing stem cell and CSC markers [3,4]. CSCs are a rare subpopulation of tumor cells thought to be responsible for cancer initiation, maintenance, growth, metastasis, recurrence, and resistance to treatments [5].…”

Section: Introductionmentioning

confidence: 99%

“…ALDH is a ubiquitously expressed intracellular enzyme that catalyzes the irreversible oxidation of a variety of cellular aldehydes. ALDH activity has been used to isolate liver stem cells [3]. Recently, ALDH1A1, a major isoform of ALDH1, has been reported as a differentiation marker for the detection of HCC.…”

Section: Introductionmentioning

confidence: 99%

Double-Staining Immunohistochemistry of Stem Cell Markers in Human Liver Cancer Tissues

Tomita¹,

Tanaka²

2015

Adv Tech Biol Med

Self Cite

View full text Add to dashboard Cite

ProcedureThe cellular markers used in the present study includes ALDH1A1 AbstractRecently, Immunohistochemistry (IHC) using specific antibodies has been exploited to detect the localization of stem cells and cancer stem cells (CSCs). Typically, there is a very small population of stem cells in normal and cancerous tissues, making it difficult to investigate their cell type and localization in human specimens. Hence, for pathological detection of human specimens, IHC has certain advantages over immunofluorescence staining. In the present study, we established a method for double-staining cancer stem cell markers and other putative markers associated with human liver cancer. We have summarized and reviewed the methodology for IHC with doublestaining in human liver cancer tissues.

show abstract

Aldehyde dehydrogenase 1A1 in stem cells and cancer

Cited by 513 publications

References 93 publications

The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma

The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma

Cancer Stem Cells and Aldehyde Dehydrogenase 1 in Liver Cancers

Double-Staining Immunohistochemistry of Stem Cell Markers in Human Liver Cancer Tissues

Contact Info

Product

Resources

About